Correction to Lancet Gastroenterol Hepatol 2025; 10: 715-25

No authors listed

Published Erratum

No authors listed. Lancet Gastroenterol Hepatol. 2025 Aug.

. 2025 Aug;10(8):e10.

doi: 10.1016/S2468-1253(25)00204-3.

No abstract available

Erratum for

Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
Feagan BG, Sands BE, Siegel CA, Dubinsky MC, Longman RS, Sabino J, Laurent O, Luo A, Lu J, Nguyen DD, Muñoz-Elias EJ, Llewellyn H, Wang Y, Jang I, Bilsborough J, Marchelletta R, Towfic F, Yen M, Anderson JK, DuVall A, Kierkus J, Woynarowski M, Al Kharrat H, Targan SR, McGovern DPB. Feagan BG, et al. Lancet Gastroenterol Hepatol. 2025 Aug;10(8):715-725. doi: 10.1016/S2468-1253(25)00071-8. Epub 2025 May 30. Lancet Gastroenterol Hepatol. 2025. PMID: 40456235 Clinical Trial.